What's the incidence of liver problems with tigecycline use?

Question

Accepted Answer

Incidence of hepatic adverse events with tigecycline

Event	Approximate frequency (based on published data)	Notes
Mild to moderate elevations in transaminases (ALT/AST)	~5–10 % of patients	Usually asymptomatic, reversible after stopping therapy; most patients have no clinical liver injury.
Hyperbilirubinemia	<3 %	Often mild; can be transient.
Severe hepatic injury (ICD‑10 codes for acute liver failure or hepatocellular injury)	<1 % (reported ≈0.03–0.1 % in large post‑marketing surveillance)	Rare but serious; usually reversible if therapy is discontinued early.
Reported fatal hepatic events	<0.01 %	Extremely rare; often associated with pre‑existing liver disease or concomitant hepatotoxic drugs.

Key points

Overall risk is low.
Most adverse liver events reported with tigecycline are mild elevations of liver enzymes that resolve after therapy stops. Serious hepatic failure is exceedingly uncommon.
Population differences.
Patients with pre‑existing liver disease, chronic alcoholism, or concomitant hepatotoxic drugs may have a slightly higher risk. The FDA prescribing information notes that “transaminase elevation is more common in patients with hepatic impairment.”
Clinical monitoring.
- Baseline liver function tests (LFTs) are recommended before starting therapy.
- Repeat LFTs after 5–7 days of therapy, or sooner if symptoms develop (e.g., jaundice, abdominal pain, fatigue).
- Discontinue tigecycline if ALT or AST rises >3 × the upper limit of normal (ULN) or if bilirubin rises >2 × ULN with symptoms.
Reporting and surveillance.
Post‑marketing data (FAERS, EudraVigilance) have identified a handful of serious hepatic events, but the numbers are very small relative to the millions of prescriptions written worldwide.

Take‑away

Incidence of mild liver enzyme elevations: ~5–10 %.
Incidence of serious hepatic injury: <1 % (≈0.03–0.1 %).
Incidence of fatal hepatic events: <0.01 %.

These figures are derived from clinical trials, post‑marketing surveillance, and regulatory safety reviews. If you are taking tigecycline and develop symptoms of liver dysfunction (e.g., yellowing of the skin or eyes, dark urine, upper‑right‑abdominal pain, unexplained fatigue), contact a healthcare professional promptly. Always discuss your personal risk factors and any concomitant medications with your prescriber.

Ask Questions, Get Industry Insights … Instantly

Recent Questions

What's the incidence of liver problems with tigecycline use?